This brochure provides a brief description of the T cell negative regulatory pathways that are frequently exploited by tumors to evade the host’s immune system. It details how researchers are targeting these immune checkpoint pathways for cancer immunotherapy and potential next generation targets for immuno-oncology research. Similar to the B7/CD28 families of T cell co-signaling molecules, many of these emerging targets also function as T cell co-inhibitory or co-stimulatory molecules, including members of the butyrophilin, CD2/SLAM, TIM, CD226, and TNF receptor families. Others, such as CD47/SIRP-alpha, IDO, LAG-3, leukocyte immunoglobulin-like receptors (LILR), CD94/NKG2A, and killer immunoglobulin-like receptors (KIRs) are molecules expressed by a variety of other immune cell types that have also been found to be utilized by tumor cells to negatively regulate anti-tumor immune responses. The brochure outlines our range of products available for researchers interested in immuno-oncology research including: